[3H] Quinuclidinyl benzylate and [3H] GABA receptor binding in rat substantia nigra after 6-hydroxy-dopamine lesions.
6-Hydroxydopamine lesions of the nigrostriatal DA pathway resulted in a 30% reduction (P less than 0.01) of nigral [3H] quinuclidinyl benzylate (QNB) binding at 3 weeks after lesion and this reduction in binding was characterised by a loss of [3H] QNB binding sites with no change in affinity. The binding of [3H] GABA to Triton-treated membranes was 12% lower (non-significant) in the nigrae of the lesioned than of the non-lesioned hemisphere, but was not characterised further. The results suggest the location of muscarinic ACh receptors on the cell bodies or dendrites of nigral DA neurons.
D000818:Animals; D003342:Corpus Striatum / Q000187:drug effects; D006892:Hydroxydopamines / Q000494:pharmacology*; D007700:Kinetics; D008297:Male; D009434:Neural Pathways / Q000187:drug effects; D016627:Oxidopamine; D011812:Quinuclidines / Q000378:metabolism*; D011813:Quinuclidinyl Benzilate / Q000378:metabolism*; D051381:Rats; D011919:Rats, Inbred Strains; D011956:Receptors, Cell Surface / Q000187:drug effects*; D011950:Receptors, Cholinergic / Q000187:drug effects*; D011954:Receptors, Dopamine / Q000187:drug effects; D011963:Receptors, GABA-A; D011976:Receptors, Muscarinic / Q000187:drug effects*; D013378:Substantia Nigra / Q000187:drug effects*; D005680:gamma-Aminobutyric Acid / Q000378:metabolism*
D006892:Hydroxydopamines; D011812:Quinuclidines; D011956:Receptors, Cell Surface; D011950:Receptors, Cholinergic; D011954:Receptors, Dopamine; D011963:Receptors, GABA-A; D011976:Receptors, Muscarinic; C028484:quinuclidinyl benzilate receptor; D005680:gamma-Aminobutyric Acid; D011813:Quinuclidinyl Benzilate; D016627:Oxidopamine